Exciting Insights and Findings Revealed in AUA 2023 Abstract Release!

Exciting Insights and Findings Revealed in AUA 2023 Abstract Release!

For over a century, the American Urological Association (AUA) has been a leading organization dedicated to supporting the urological community. With more than 23,000 members worldwide, AUAs mission is to promote the highest standards of urological care through education, research, and healthcare policy. AUA has played a crucial role in advancing the field of urology.

This year, the AUA Annual Meeting will be held in Chicago, IL, in a hybrid model, from April 28 to May 1, 2023. The conference has released 3,454 abstracts, offering a glimpse into the exciting new research and findings that will be presented at the conference.

Ferma.AI has identified the most significant and anticipated sessions that are expected to generate the highest levels of interest among the attendees. Want to improve your conference coverage with Ferma.AI? Schedule a demo to learn how to enhance insights and velocity while reducing costs by 40%.

Exploring the Latest Developments in Androgen Receptor Inhibitors

Treatment Duration And Long-Term Safety And Tolerability With Darolutamide In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc): Aramis Rollover Study

ARAMIS | NCT02200614 | Non-Metastatic Castration-Resistant Prostate Cancer | Bayer & Orion Pharma | Abstract

The ARAMIS Rollover Study (ROS) of Bayer and Orion Pharma evaluated the long-term safety and tolerability of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). DARO treatment duration ranged from 0-6.8 years, with approximately 30% of patients receiving treatment for ≥4 years. Cumulative incidences of treatment-emergent adverse events (TEAEs) increased slightly with longer observation time, but the favorable safety profile of DARO was maintained with long-term exposure. No new safety concerns were observed in the ROS.

The Effect Of A Reduced Dose Of Apalutamide On Skin-Related Adverse Events In Advanced Prostate Cancer: A Multicenter Retrospective Study

PROpel | NCT05171816 | Advanced Prostate Cancer | AstraZeneca & Merck Sharp & Dohme | Abstract

This retrospective study PROpel by AstraZeneca and Merck Sharp & Dohme evaluated the effect of apalutamide dose reduction on skin-related adverse events and castration-resistant prostate cancer (CRPC)-free survival in patients with advanced prostate cancer. The skin adverse events (AE) rate was not significantly different between full and reduced dose groups, but dose reduction in patients with small body size led to a lower incidence rate of skin AEs. The apalutamide discontinuation rate after skin AEs was significantly lower in the reduced dose group. The CRPC-free survival was not significantly different between full and reduced dose groups.

Real-World Study On Darolutamide, Enzalutamide, And Apalutamide For Nonmetastatic Castration-Resistant Prostate Cancer Patients Using A Urology Network In The United States (Dear Study)

DEAR | NCT05362149 | Non-Metastatic Castration-Resistant Prostate Cancer | Bayer | Abstract

Bayer’s DEAR study assessed the real-world utilization and outcomes of darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer. In total, 666 patients were included, with fewer patients discontinuing treatment or progressing to metastatic CRPC in the darolutamide cohort compared to enzalutamide or apalutamide. The estimated probability of discontinuation/progression was also numerically lower for darolutamide. These findings suggest that darolutamide may be a more tolerable treatment option for patients with nmCRPC.

Breaking Down the Latest PD-1 Inhibitors Research

Outcomes In Patients (Pts) With Bacillus Calmette-Guerin (Bcg)-Unresponsive High-Risk (Hr) Non-Muscle-Invasive Bladder Cancer (Nmibc) Who Underwent Radical Cystectomy (Rc) Following Pembrolizumab (Pembro) Treatment In Keynote-057 Cohort A

Keynote-057 | NCT02625961 | High Risk Non-Muscle Invasive Bladder Cancer | Merck Sharp & Dohme | Abstract

In a retrospective analysis of KEYNOTE-057 cohort A by Merck Sharp & Dohme, pembrolizumab treatment resulted in a complete response (CR) rate of 41% and a median duration of response of 16.2 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR NMIBC) with carcinoma in situ (CIS)±papillary disease. Of the 96 enrolled patients, 43 underwent radical cystectomy (RC) after discontinuing pembrolizumab, with a median time to RC of 9.0 months. Five patients had upstaging to MIBC, but the delay in RC may provide a window of opportunity for some patients to avoid or delay surgery.

Assessment Of Surgical Complications In Patients With Metastatic Clear Cell Renal Cell Carcinoma (Mccrcc) Receiving Perioperative Cabozantinib And Nivolumab On Cyto-Kik Clinical Trial

Cyto-KIK | NCT04322955 | Metastatic Clear Cell Renal Cell Carcinoma | Bristol-Myers Squibb & Exelixis | Abstract

BMS & Exelixis’s Cyto-KIK phase  2 trial evaluated 16 patients with metastatic clear cell renal cell carcinoma who were given cabozantinib and nivolumab for 12 weeks prior to cytoreductive nephrectomy. The safety of the interval between the discontinuation of cabozantinib and nephrectomy was evaluated using a 3+3 design. Three evaluable patients completed nephrectomy within the 21-day interval and 5 within the 14-day interval after discontinuation of cabozantinib. There were no treatment-related surgical complications and no delays in resuming combination systemic therapy after surgery.

First Results From Sunrise-1 In Patients With Bcg Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer Receiving Tar-200 In Combination With Cetrelimab, Tar-200, Or Cetrelimab Alone

SunRISE-1 | NCT04640623 | High-Risk Non Muscle Invasive Bladder Cancer | Janssen | Abstract

The SunRISe-1 study of Janssen evaluated the efficacy and safety of TAR-200, a novel intravesical drug delivery system, and cetrelimab (CET), an anti-PD1 agent, in BCG-unresponsive patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC). Preliminary data from TAR-200 monotherapy showed an 88% confirmed complete response (CR) rate, and 85% of patients had treatment-emergent adverse events (TEAEs). CET results were consistent with other anti-PD(L)1 treatments. These initial results support continued study of TAR-200 and CET in HR NMIBC.

Future Perspective

Ferma.AI tracks abstract and data releases for all major healthcare conferences, alongside social media and healthcare news reactions. Interested in learning more about how Ferma.AI can enhance your conference coverage and insights while also reducing costs by 40%? Schedule a brief call with us to see a live demonstration.